Pakistan Faces Shortage of Popular Insulin Brand: National Assembly Told

Pakistan is facing a shortage of the insulin brand Apidra after its German manufacturer suspended production for upgrades, the National Assembly was informed.

Key points

• Responding to reservations raised by MNA Syeda Amna Batool, Azeem stated the manufacturer previously supplied 3, 500 kits, but the number had dropped to 1, 000.
• Health ministry spokesperson Sajid Shah remarked alternative rapid-acting insulin products, including NovoRapid by Novo Nordisk and Humalog by Eli Lilly, remained available nationwide.
• Parliamentary Secretary for Health Nelson Azeem remarked the shortage began in October after supplies from Germany were disrupted.
• Nevertheless, Azeem maintained that alternative insulin products with similar dosages and mechanisms of action were available in Pakistan and could be employed on doctors' recommendations.
• Although Azeem acknowledged that securing the product would be challenging while production remained suspended, the health ministry has asked distributors to arrange extra supplies.

Parliamentary Secretary for Health Nelson Azeem remarked the shortage began in October after supplies from Germany were disrupted. The product had remained available in Pakistan until September. Scientists Discover 31 New Genetic Regions Linked to Fatty Liver Disease.

Responding to reservations raised by MNA Syeda Amna Batool, Azeem stated the manufacturer previously supplied 3, 500 kits, but the number had dropped to 1, 000. He cautioned that supplies could decline further during the company's year-long upgrade process.

He continued that the disruption was affecting a number of regions, including Asia, Australia, and Europe, and that supplies would resume once international production and distribution returned to normal.

Meanwhile, Batool expressed concern over the availability and affordability of alternative insulin products. She remarked alternatives were at least 20% more expensive and that numerous patients lacked access to doctors who could guide them through switching treatments. Punjab Opens MBBS Admissions for Private Medical Colleges.

Earlier this week, the health ministry clarified that Pakistan was not facing a nationwide insulin shortage and that the supply matter was limited to insulin glulisine (Apidra), manufactured by Sanofi.

Health ministry spokesperson Sajid Shah remarked alternative rapid-acting insulin products, including NovoRapid by Novo Nordisk and Humalog by Eli Lilly, remained available nationwide. Other major insulin categories were additionally available nationwide. Stay Connected with ProPakistani. Obtain the latest news and stories wherever you prefer. Follow on Google Discover. Follow on Google News Join WhatsApp. See more ProPakistani stories in Google Search and Top Stories.

For now, pakistan Faces Shortage of Popular Insulin Brand: National Assembly Told remains the part of the story worth watching, and further updates are likely as more details are confirmed.